OMIDRIA
Peakphenylephrine and ketorolac
NDAIRRIGATIONSOLUTION
Approved
May 2014
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
3/8 — Basic
OMIDRIA (phenylephrine and ketorolac) is cyclooxygenase inhibitors [moa]. First approved in 2014.
Drug data last refreshed 2h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
OMIDRIA is a fixed-dose combination intraocular irrigation solution containing phenylephrine (sympathomimetic) and ketorolac (NSAID) for use during cataract surgery. It maintains mydriasis and reduces miosis during the procedure while providing anti-inflammatory protection. The dual mechanism addresses both hemodynamic and inflammatory challenges in ophthalmic surgery.
Peak7.5 years to LOE
Product is at peak lifecycle with no identified direct competitors, suggesting stable market position and established commercial infrastructure supporting the brand team.
Mechanism of Action
Cyclooxygenase Inhibitors
Pharmacologic Class:
Nonsteroidal Anti-inflammatory Drug
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
OMIDRIA represents a stable, niche specialty pharmaceutical career opportunity positioned in ophthalmic surgery with established market presence and zero competitive pressure. Career progression on this product emphasizes field execution, account management, and market optimization rather than new indication development or launch dynamics.
Brand Manager
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.